Neuroendocrine Markers Insulinoma-Associated Protein 1, Chromogranin, Synaptophysin, and CD56 Show Rare Positivity in Adenocarcinoma Ex-Goblet Cell Carcinoids.
Adenocarcinoma ex-goblet cell carcinoid
Chromogranin
Insulinoma-associated protein 1
Neuroendocrine
Synaptophysin
Journal
Gastroenterology research
ISSN: 1918-2805
Titre abrégé: Gastroenterology Res
Pays: Canada
ID NLM: 101519422
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
05
01
2019
accepted:
21
01
2019
entrez:
26
6
2019
pubmed:
27
6
2019
medline:
27
6
2019
Statut:
ppublish
Résumé
Adenocarcinoma ex-goblet cell carcinoid (AdexGCC) was considered a neuroendocrine adenocarcinoma, despite majority of tumor cells being negative for conventional neuroendocrine markers such as chromogranin and synaptophysin. Recently, insulinoma-associated protein 1 (INSM1) has been identified as a novel neuroendocrine marker that is more sensitive than chromogranin, synaptophysin, and CD56 in pulmonary neuroendocrine tumors. We studied this marker in conjunction with chromogranin, synaptophysin, and CD56 in 36 appendiceal AdexGCCs (21 primaries, 15 metastatic). Primary AdexGCCs showed staining for INSM1, chromogranin, synaptophysin, and CD56 in 13/21 (62%), 18/21 (86%), 18/21 (86%), and 9/19 (47%) cases, respectively. However, the mean proportion of tumor cells stained for INSM1, chromogranin, synaptophysin, and CD56 was only 8.0% (median 1%, range 0-70%), 15.7% (median 2%, range 0-70%), 19.9% (median 5%, range 0-90%), and 5.6% (median 0%, range 0-50%), respectively. Metastatic AdexGCCs showed staining for INSM1, chromogranin, synaptophysin, and CD56 in 8/15 (53%), 11/15 (73%), 12/15 (80%), and 3/14 (21%) cases. The mean proportion of tumor cells stained for INSM1, chromogranin, synaptophysin, and CD56 in metastatic tumors was 1% (median 1%, range 0-3%), 12% (median 1%, range 0-85%), 17% (median 5%, range 0-85%), and 2% (median 0%, range 0-20%), respectively. Primary and metastatic AdexGCCs showed no difference in INSM1, chromogranin, synaptophysin, or CD56 staining. INSM1 exhibits low expression in AdexGCCs and is expressed by a lower proportion of tumor cells compared to chromogranin and synaptophysin.
Sections du résumé
BACKGROUND
BACKGROUND
Adenocarcinoma ex-goblet cell carcinoid (AdexGCC) was considered a neuroendocrine adenocarcinoma, despite majority of tumor cells being negative for conventional neuroendocrine markers such as chromogranin and synaptophysin. Recently, insulinoma-associated protein 1 (INSM1) has been identified as a novel neuroendocrine marker that is more sensitive than chromogranin, synaptophysin, and CD56 in pulmonary neuroendocrine tumors.
METHODS
METHODS
We studied this marker in conjunction with chromogranin, synaptophysin, and CD56 in 36 appendiceal AdexGCCs (21 primaries, 15 metastatic).
RESULTS
RESULTS
Primary AdexGCCs showed staining for INSM1, chromogranin, synaptophysin, and CD56 in 13/21 (62%), 18/21 (86%), 18/21 (86%), and 9/19 (47%) cases, respectively. However, the mean proportion of tumor cells stained for INSM1, chromogranin, synaptophysin, and CD56 was only 8.0% (median 1%, range 0-70%), 15.7% (median 2%, range 0-70%), 19.9% (median 5%, range 0-90%), and 5.6% (median 0%, range 0-50%), respectively. Metastatic AdexGCCs showed staining for INSM1, chromogranin, synaptophysin, and CD56 in 8/15 (53%), 11/15 (73%), 12/15 (80%), and 3/14 (21%) cases. The mean proportion of tumor cells stained for INSM1, chromogranin, synaptophysin, and CD56 in metastatic tumors was 1% (median 1%, range 0-3%), 12% (median 1%, range 0-85%), 17% (median 5%, range 0-85%), and 2% (median 0%, range 0-20%), respectively.
CONCLUSIONS
CONCLUSIONS
Primary and metastatic AdexGCCs showed no difference in INSM1, chromogranin, synaptophysin, or CD56 staining. INSM1 exhibits low expression in AdexGCCs and is expressed by a lower proportion of tumor cells compared to chromogranin and synaptophysin.
Identifiants
pubmed: 31236152
doi: 10.14740/gr1138
pmc: PMC6575132
doi:
Types de publication
Journal Article
Langues
eng
Pagination
120-127Déclaration de conflit d'intérêts
None of the authors have any relationships with, or financial interest in, any commercial companies pertaining to this article
Références
Arch Pathol Lab Med. 2001 Mar;125(3):386-90
pubmed: 11231488
J Biol Chem. 1992 Jul 25;267(21):15252-7
pubmed: 1634555
Nat Rev Genet. 2006 May;7(5):349-59
pubmed: 16619050
Am J Surg Pathol. 2007 Oct;31(10):1502-11
pubmed: 17895750
Histopathology. 2007 Dec;51(6):763-73
pubmed: 18042066
Am J Clin Pathol. 2015 Oct;144(4):579-91
pubmed: 26386079
Am J Pathol. 2015 Dec;185(12):3164-77
pubmed: 26482608
Mod Pathol. 2016 Oct;29(10):1243-53
pubmed: 27338636
Am J Surg Pathol. 2017 Nov;41(11):1561-1569
pubmed: 28719469
Am J Surg Pathol. 2018 Feb;42(2):160-171
pubmed: 28914716
Mod Pathol. 2018 May;31(5):829-839
pubmed: 29327707
Mod Pathol. 2018 Jun;31(6):989-996
pubmed: 29422640
Am J Surg Pathol. 2018 Jul;42(7):898-910
pubmed: 29579011
Hum Pathol. 2018 Jul;77:166-174
pubmed: 29634977
Gastroenterology Res. 2018 Jun;11(3):221-230
pubmed: 29915633
Cancer. 1971 Oct;28(4):990-8
pubmed: 4106849
Cancer. 1974 Aug;34(2):338-44
pubmed: 4852178
Cancer. 1979 Nov;44(5):1700-6
pubmed: 498041
Am J Surg Pathol. 1981 Apr;5(3):213-24
pubmed: 7235117
Cancer. 1978 Dec;42(6):2781-93
pubmed: 728874